Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Russia hurts Dr Reddy's in Q1 but US NDAs progress

This article was originally published in Scrip

Executive Summary

Dr Reddy's Laboratories reported a 7% increase in revenues to INR37.6bn ($591m) for the first quarter ended June, but growth was impacted by a significant drop in sales in emerging markets and flat numbers in the pharmaceutical services and active ingredients (PSAI) business. Net profits increased by 14% to INR6.3bn.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts